Share on StockTwits

Shire PLC (LON:SHP)‘s stock had its “outperform” rating restated by analysts at BNP Paribas in a research report issued to clients and investors on Thursday. They currently have a GBX 3,600 ($61.32) price objective on the stock. BNP Paribas’ price target would suggest a potential downside of 20.79% from the company’s current price.

SHP has been the subject of a number of other recent research reports. Analysts at Cenkos Securities Ltd raised their price target on shares of Shire PLC from GBX 4,005 ($68.22) to GBX 5,200 ($88.57) in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Shire PLC in a research note on Wednesday. They now have a GBX 3,700 ($63.02) price target on the stock. Finally, analysts at AlphaValue reiterated a “reduce” rating on shares of Shire PLC in a research note on Friday, June 27th. They now have a GBX 4,599 ($78.33) price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of GBX 3,365.68 ($57.33).

Shire PLC (LON:SHP) opened at 4597.9751 on Thursday. Shire PLC has a 52-week low of GBX 2069.00 and a 52-week high of GBX 4686.022. The stock’s 50-day moving average is GBX 3718.89 and its 200-day moving average is GBX 3243.41. The company’s market cap is £26.866 billion.

Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.